Rexahn Pharmaceuticals

Rexahn Pharmaceuticals, Inc. (NASDAQ: REXN) is a biopharmaceutical company dedicated to developing novel targeted therapies in the clinical stage for cancer treatment. The company's mission is to improve patients' lives by enhancing the efficacy of treatments for difficult-to-treat cancers through the development of a new generation of cancer therapies, which aim to maximize effectiveness while minimizing the toxicity and side effects associated with traditional cancer treatments. Rexahn’s candidate products work by targeting and neutralizing specific proteins that are believed to be involved in the complex biological cascades leading to cancer cell growth. Preclinical studies indicate that some of Rexahn’s candidate products may be effective against various types of cancer, including drug-resistant, hard-to-treat cancers, as well as others that could enhance the effectiveness of currently FDA-approved cancer treatments. The company’s oncology pipeline, which has either entered preclinical or clinical trials, includes RX-3117, RX-5902, and RX-0301.